"The letters of intent and commercial agreement are major milestones for Medicsight in reaching our goal of being the leading global supplier of medical imaging analysis software", stated Paul Samuel, Medicsight CEO. "We look forward to working with Agfa, Vital Images, and Viatronix to integrate our software into their systems. We believe these partnerships demonstrate the significant value of the Medicsight software and clearly show how our software can differentiate existing offerings of imaging companies."
Medicsight's software will be demonstrated at the exhibitor booths of Agfa, Vital Images, and Viatronix during the annual meeting of the Radiological Society of North America (RSNA). The RSNA trade show opens November 28 and runs through December 3 at McCormick Place in Chicago.
"Integrating the Medicsight portfolio in our market leading solution fits into our strategy of offering best-of-breed solutions to the radiologist and clinician through intelligent strategic alliances", stated Etienne Vanderstokker, head of Medical Imaging Technologies, Business Group Healthcare, Agfa. "It's a successful and award-winning strategy that has been fully appreciated by the market and has strengthened Agfa's capability to penetrate new markets and to remain on top of technological innovations."
The Agfa-Gevaert Group is one of the world's leading imaging companies. Agfa develops, manufactures and markets analogue and digital systems, intended mainly for the graphics industry and the health care markets. Agfa's headquarters are in Mortsel, Belgium. The company is active in 40 countries and has agents in another 100 countries throughout the world. Together they achieved a turnover of 4215 million euros in 2003.
Vital Images will be integrating Medicsight's Colon CAR software into its CT colon product InnerviewGI. "We are excited about further enhancing our colon offering with Medicsight's CAR image-analysis technology", stated Jay D. Miller, president and chief executive officer, Vital Images. "This partnership together further demonstrates our commitment to the oncology marketplace and more specifically to the application of virtual colonoscopy."
In October 2004, Medicsight received FDA approval for its Colon CAR 1.2, an image analysis software tool designed to be used with CT colonography, virtual colonoscopy, to assist radiologists in searching for and measuring potential colorectal polyps. The software also supports radiologists in accurately reviewing and tracking any polyp growth.
"We are delighted to partner with Vital Images, which has a well-regarded CT colon option and growing customer base", stated Jamshid Dehmeshki, Medicsight chief technology officer. "We believe our Colon CAR tool will significantly improve the productivity of radiologists reading CT colonography exams."
Medicsight Colon CAR 1.2 uses the company's Computer Assisted Reader (CAR) technology to deploy a series of filters against image data derived from CT colonographies. These filters highlight spherical areas of the image as small as 5 mm which could be potential polyps. The radiologist is also able to manually highlight any irregularities for closer inspection. Once suspect polyps are found, the software can precisely identify the boundaries and features, and show them in 3D with a volume measurement, diameters, shape and location. Colon CAR is the first joint-read software product available for CT scans of the colon.
Vital Images, headquartered in Minneapolis, Minnesota, is a provider of advanced medical imaging software for use in disease screening applications, clinical diagnosis and therapy planning. The company's technology utilizes high-speed volume visualization and analysis, as well as network communications based on DICOM and Internet protocols. Vital Images cost-effectively brings advanced visualization and analysis into the day-to- day practice of medicine.
The letter of intent signed by Viatronix and Medicsight includes Medicsight's Lung CAR and Colon CAR software. "We believe computer assisted read (CAR) technology provides an important tool for the radiologist and greatly enhances their diagnostic capability", stated Zaffar Hayat, CEO and president of Viatronix Incorporated. "The integration of Medicsight's Lung and Colon CAR software with our products will greatly complement our advanced medical imaging solutions."
Medicsight Lung CAR is an image-analysis software tool that assists radiologists in evaluating lesions or nodules found during CT scans of the lung. Medicsight Lung CAR 1.1 received FDA clearance in August 2004. Lung CAR is the first joint-read software product available for CT scans of the lung.
Viatronix, located in Stony Brook, New York, is an innovator and developer of diagnostic 3D imaging software, which enables physicians to interactively view patients' vital organs and anatomical structures. The Viatronix PACS-integratable V3D-Explorer has patent protected technology that enables 3D visualization of organs from patient data acquired by standard imaging equipment via minimally invasive or non-invasive methods.
The Viatronix V3D-Colon allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the inner surface of the colon, including polyps. The Viatronix V3D-Calcium Scoring aids physicians in determining the amount of calcium plaque accumulation in the coronary arteries. V3D-Vascular is the latest addition to the V3D System. In seconds, this breakthrough software permits rapid segmentation and visualization of complex arterial structures using 3D volume rendering, maximum intensity projection and simulated x-ray views. Viatronix, through application of its V3D technology, is developing additional innovative products that will be useful for earlier detection of diseases, treatment planning, and follow-up evaluation.
Medicsight Heart Screen is an update to the company's MedicHeart 1.0 heart imaging software that features a newly designed user interface. Medicsight Heart Screen is an image-analysis software tool for CT scans that assists radiologists and cardiologists in identifying and quantifying coronary artery calcification.
Paul Samuel stated that Medicsight would continue to pursue other distribution agreements as well. "We're looking for quality partners who share our vision of taking software beyond detection to diagnosis and patient management and who can help broaden our reach in the marketplace", he said. "We will also continue to focus on deepening our established relationships."
Medicsight is a software development business focused on the medical imaging market. The company is using its core technology to develop automatic detection and analytical tools for clinicians to improve their ability to diagnose and treat disease, initially focusing on three key clinical areas such as lung cancer, colon cancer, and coronary heart disease. Medicsight's software will enable earlier and more accurate detection and treatment of suspicious lesions, which can save lives and reduce health care costs. Headquartered in London, Medicsight employs more than 60 people and has offices in the United Kingdom, the United States, and China. Since its inception in 1999, Medicsight has been developing its core algorithms through a team of more than 30 scientists and software developers.